It depends which type of program you're looking at.
For example, on a capital program, a conditionally repayable loan works out very well. On higher-risk R and D, particularly IRAP's program is geared towards that. They want to be way out there in terms of leading-edge research and development. That tends to be more of a grant, because that's the sphere they play with.
You have to look at what you are doing. When we're doing a capital expansion, one of the things that was absolutely excellent about ACOA was they provided repayable loans, but they don't take in security, and because they don't do that, we can then go to our banks and provide them with the security, get three-quarters of the financing from them, and then finish it off with ACOA-type money, which has been very useful for our growth in the past.